Cardioprotection on Chemotherapy-Induced Cardiotoxicity
ConditionCardiotoxicity
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age1-18
SponsorAin Shams University
About this trial
The aim of the present study is to evaluate the protective impact of cardioprotective medications on the chemotherapy- induced cardiotoxicity.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Willingness of the legal representative of research participant to participate in the study by giving "informed consent."
Ability to take oral medication.
Age 2-18 years at the time of diagnosis.
Disqualifiers
Documented allergy to cardioprotective medications
Trial design
Design model
Parallel
Treatments tested in this trial
ACE Inhibitors
Drug0.3 mg/kg/dose every 8 hours orally by either a caregiver or caring nurse.
β -Blockers
Drug0.05 mg/kg/dose every 12 hours orally by either a caregiver or caring nurse.
Treatment groups
30 Participants
are divided into 2 treatment groupsGroup A: ACEIsActive comparator 1 intervention
Group B: β-blockersActive comparator 1 intervention
Trial outcomes
Primary outcomes
1
Change in Left Ventricular Ejection Fraction (LVEF)
he LVEF will be measure by 2D Echocardiography at baseline and at the end of Induction Phase (42 Days)
Time frame
LVEF will be measured at Baseline and at the end of Induction Phase (42 Days)Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov